Literature DB >> 3518602

Prospects for immunotoxin therapy in cancer.

A E Frankel, L L Houston, B F Issell, G Fathman.   

Abstract

Immunotoxins are formed by chemically linking antibodies to "toxic" polypeptides that inactivate protein synthesis. These hybrid protein molecules are guided to tumor cells by the antibody moiety, and once bound to the tumor cells, the toxic polypeptide moiety penetrates the cell membrane and enzymatically inactivates protein synthesis. A stepwise approach to identifying the potential clinical uses of immunotoxins in cancer therapy is examined in this chapter.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3518602     DOI: 10.1146/annurev.me.37.020186.001013

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  16 in total

1.  Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function.

Authors:  R A Rasmussen; S L Counts; J M Lambert; A R Collinson
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  Tissue culture of endod (Phytolacca dodecandra L'Herit): growth and production of ribosome-inactivating proteins.

Authors:  M S Bonness; T J Mabry
Journal:  Plant Cell Rep       Date:  1992-03       Impact factor: 4.570

Review 3.  Monoclonal antibodies as magic bullets.

Authors:  F M Brodsky
Journal:  Pharm Res       Date:  1988-01       Impact factor: 4.200

4.  An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.

Authors:  A A Hertler; D M Schlossman; M J Borowitz; D G Poplack; A E Frankel
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.

Authors:  J J Starling; R S Maciak; N A Hinson; C L Nichols; S L Briggs; B C Laguzza
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Targeted delivery of saporin toxin by monoclonal antibody to the transcobalamin receptor, TCblR/CD320.

Authors:  Edward V Quadros; Yasumi Nakayama; Jeffrey M Sequeira
Journal:  Mol Cancer Ther       Date:  2010-09-21       Impact factor: 6.261

7.  Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.

Authors:  L Cattel; L Delprino; P Brusa; F Dosio; P M Comoglio; M Prat
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Selective cytotoxicity of an oxygen-radical-generating enzyme conjugated to a monoclonal antibody.

Authors:  M G Battelli; A Abbondanza; P L Tazzari; A Dinota; S Rizzi; G Grassi; M Gobbi; F Stirpe
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

9.  Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.

Authors:  J M Trang; A F LoBuglio; R H Wheeler; E B Harvey; L Sun; J Ghrayeb; M B Khazaeli
Journal:  Pharm Res       Date:  1990-06       Impact factor: 4.200

10.  Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.

Authors:  R Orlandi; S Canevari; F P Conde; F Leoni; D Mezzanzanica; M Ripamonti; M I Colnaghi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.